期刊
ACS INFECTIOUS DISEASES
卷 5, 期 1, 页码 131-140出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsinfecdis.8b00246
关键词
antibiotic resistance; metallo-beta-lactamase inhibitor; NDM-1; VIM-2; meropenem; efficacy
资金
- Wellcome Trust [099212/Z/12]
The clinical effectiveness of carbapenem antibiotics such as meropenem is becoming increasingly compromised by the spread of both metallo-beta-lactamase (MBL) and serine-beta-lactamase (SBL) enzymes on mobile genetic elements, stimulating research to find new beta-lactamase inhibitors to be used in conjunction with carbapenems and other beta-lactam antibiotics. Herein, we describe our initial exploration of a novel chemical series of metallo-beta-lactamase inhibitors, from concept to efficacy, in a survival model using an advanced tool compound (ANT431) in conjunction with meropenem.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据